Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human open-label single ascending dose study of subretinal CPK850 for RLBP1-associated retinitis pigmentosa
2023-508688-54-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2024
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CPK850 in retinitis pigmentosa (RP), sponsored by Novartis. Primary endpoints: Number of participants with adverse events, serious adverse events, and deaths and Number of responders in dark adaptation. Started Jan 2024; status: completed.
02
Drugs
CPK850
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on 2023-508688-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508688-54-00.